| Involved Organisation | Type | Further fields of acitivity | Focus | based in | Management | was foundet in | Address | Homepage | Profile | Contact | Number of employees | Certificates | BioChancePlus | BioProfile | Scientific Advisory Board | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DR. PETRY genmedics GMBH | Biotech | Medicine, Nutrigenomics | Staphylococcus research | Reutlingen | Justus Dehnen (CEO) Dr. Jörg Petry (CFO) Dr. Bernhard Krismer (CSO) Dr. Günther Thumm (COO) | Ferdinand-Lassalle-Strasse 57 72770 Reutlingen Germany Tel.: +49 (0)7121-95890 Fax: +49 (0)7121-958933 | info@genmedics.com | www.genmedics.com | DR. PETRY genmedics GmbH focuses on research into the Staphylococcus organism. The biotechnology firm, which has bases in Reutlingen and Tübingen, is not only seeking to combat the disease pathogen but also use it as a carrier agent for various active agents. The pathogen Staphylococcus epidermidis is capable of forming a biofilm on a range of surfaces. Thanks to its high levels of resistance to a wide range of antibiotics, pathogenic Staphylococci are becoming a major hazard in the field of medicine in the context of biofilm-related, foreign-body infections. It is for this area of activity that DR. PETRY genmedics offers an evaluation of materials for biofilm formation. As a result, new medical materials such as foreign-body implants can be checked for their biofilm formation properties. In addition to working with pathogenic Staphylococci, the firm also focuses on the expression of therapeutically-effective proteins in the food-grade bacterium S. carnosus. | Dr. Jörg Petry | Optimisation of the expression and purification of two staphylolytic active agents | Associated project NAPRAS; Development of new agents against biofilm formation on regenerative and synthetic tissue implants; Subproject 2: Assay development, screening, verification | Prof. Friedrich Götz Prof. Günther Jung P Prof. Joachim-Volker Höltje Prof. Rolf G. Werner | |||
| immatics biotechnologies GmbH | Biotech | Drug Development, Medicine | Immune therapy, oncology | Tübingen | Paul G. Higham (CEO) Dr. Carsten Reinhardt (CMO) Dr. Harpreet Singh (CSO) | 2000 | Paul-Ehrlich-Strasse 15 72076 Tübingen Germany Tel. +49 (0)7071-5651250 Fax +49 (0)7071-56512599 | info@immatics.com | www.immatics.com | immatics is a biopharmaceutical company dedicated to the development of innova¬tive cancer immunotherapeutics. immatics' proprietary technology for the identification of tumor-associated pep¬tides (TUMAPs) enables the development of novel anti-cancer vaccines for multiple cancer indications. immatics is currently developing two multi-TUMAP products in clinical phase II studies – IMA901 for the treatment of renal cell carcinoma (RCC) and IMA910 for the treatment of colorectal carcinoma (CRC). Further product candi¬dates are currently in pre-clinical de¬velopment. With its unique proprietary XPRESIDENT™ discovery platform, immatics is constantly identifying very large numbers of naturally-presented tumor-associated peptides (TUMAPs) directly from primary tumor tissue. Since 2004 alone, the company has identified more than 50,000 TUMAP sequences and has secured the IP rights for those with high potential for use in cancer therapy. immatics identifies TUMAPs which occur as natural ligands of HLA class I and II-receptors. These TUMAPs can activate cyto¬toxic T cells and T helper cells, key players of the cellular immune response, which have the ability to eradicate cancer cells once they are primed effectively. TUMAPs are short peptides which are excellent drug candidates. They can be syn¬thesized and characterized by established, robust and fully scalable chemistry. | Dr. Harpreet Singh | 65 | “PROstat – regenerating micturition function in benign prostatic hyperplasia through immune therapy” Identification, selection and validation of tumour-related peptides in stomach carcinomas aimed at defining a therapeutic vaccine based on immunogenic peptide epitopes. | Prof. Hans-Georg Rammensee Prof. Cornelius Melief Prof. Christoph Huber Prof. Craig Slingluff | ||
| Insilico Biotechnology AG | Biotech | Laboratory Techniques, Information Technology | System biological research | Stuttgart | Klaus Mauch | 2001 | Nobelstrasse 15 70569 Stuttgart Germany Tel.: +49 (0)711-674 2164 Fax: +49 (0)711-674 2166 | info@insilico-biotechnology.com | www.insilico-biotechnology.com | Insilico Biotechnology designs and optimizes biotech processes for the chemical, pharmaceutical, agricultural and food industries. Insilico boasts internationally recognized expertise and the world's only system biology platform combining proprietary databases, cell models and computer-controlled evaluation methods. By integrating and evaluating experimental data using genome-wide network models, Insilico offers new solutions for manufacturing biochemicals and biopharmaceuticals, validates active substances and reduces drug development periods. Founded as a spin-off of the University of Stuttgart in 2001, Insilico currently employs eight staff. The company, which was converted into a joint-stock company in July 2006, is headed by Klaus Mauch. Since 2005, Insilico Biotechnology AG as an industrial partner in the federal HepatoSys competence network has been performing computer-based mapping and testing of liver cell metabolism. Insilico is responsible in particular for determining kinetic parameters using supercomputers. The aim is to model a »virtual liver cell« to enable physiological cell processes – such as the breakdown of drugs and toxic substances – to be followed »in silico«. For the second project phase, Insilico will receive Euro 250,000 of funding over the next three years. | Klaus Mauch | 8 | Prof. Matthias Reuss Prof. Rolf D. Schmid Prof. Bernard Witholt Prof. Dr. Stefan Schuster | |||
| ExploSys | Biotech | Services, Information Technology | Simulation of biological systems | Leinfelden-Echterdingen | PD Dr. Martin Eichner Dr. Hans-Peter Duerr Dr. Markus Schwehm | 2005 | Westbahnhofstrasse 55 72070 Tübingen Germany Tel.: +49 (0)7071-2978250 Fax: +49 (0)7071-295383 | info@explosys.de | www.explosys.de | The three Explosys scientists work on the basis that even seemingly simple problems in public health are caused by complex, interacting factors and thus require customised solutions. Using mathematical models and computer simulations, they aim to create innovative and flexible solutions for precisely such problems. Of course, such models are also intended to advance fundamental research into epidemiological modelling. Realistically-simulated infection outbreaks are intended to train physicians and people in positions of responsibility in how to bring potential epidemics under control through fast and efficient intervention. “InterSim” is a computer model that can authentically simulate the progress of a spreading infection. It enables recommendations to be derived for decision-makers, for example, those in public health roles. InterSim has since received multiple awards, including the “Special Prize for Open Source Software” in October 2004 from the Business Initiative Baden-Württemberg: connected (bwcon). A simulator, based on InterSim, was developed following a commission from the BGMS (German Federal Ministry of Health and Social Security) and is currently being used by the Robert Koch Institute to develop efficient interventional strategies for epidemics. The "Influenza-Pandemic-Planning-Simulator" InfluSim enables the prediction of the temporal course of an influenza pandemic. The software can be downloaded from http://www.uni-tuebingen.de/modeling/Mod_Pub_Software_de.html. | Dr. Markus Schwehm (Markus.Schwehm@explosys.de) | K. Auranen K. Dietz G. Sallet A. Spielman | ||||
| M-fold Biotech GmbH | Biotech | Services, Proteomics | Structural analyses, in vitro bonding and functional testing of membrane proteins, production of antibodies | Tübingen | Dr. Hans Kiefer, Scientific Director Dr. Wolfgang Vogt, Managing Director | 1999 | Vor dem Kreuzberg 17 72070 Tübingen Germany Tel.: +49 (0)7071-7945-0 Fax: +49 (0)7071-7945-11 | contact@m-phasys.com | www.m-phasys.com | M-fold Biotech was founded in 1999 as m-phasys by Dr. Hans Kiefer, Dr. Wolfgang Vogt, Marc Lohrmann and i.con. innovation GmbH. Membrane proteins are the most commercially-interesting target proteins for medications and represent M-fold Biotech GmbH’s core area of expertise yet they are also the most difficult to work with. The key to the firm’s success was the use of the patented M-FOLD technology, which was used to manufacture membrane protein antigens. Using two very different methods (immunisation and “phage display” selection), the firm succeeded in manufacturing antibodies with the required binding properties and biological activity and selectivity. In addition to structural analysis, m-phasys has recently established a new area of business, namely the manufacture of antibodies that act against membrane proteins and can themselves act as medications. M-fold Biotech's customers include major pharmaceutical companies who commission the structural analyses in order to develop medications. | 12 | Structural explanations of therapeutically-relevant potassium channels | Associated project: Joint project into the generation of antibodies against frizzled receptors (GPCRs) for the isolation and characterisation of stem cells. | |||
| CureVac GmbH | Biotech | Drug Development, Medicine, Trade/Distribution | CureVac GmbH specialises in RNA molecules synthesised by chemical and enzymatic means. CureVac also carries out its own research in the field of tumour therapy. | Tübingen | Dr. Ingmar Hörr (CEO) Dr. Thomas Lander (CMO) Dr. Florian von der Mülbe (COO) Dr. Wolfgang Klein (CFO) Dr. Jochen Probst (CSO) | 2000 | Paul-Ehrlich-Str. 15 72076 Tübingen Germany Tel: +49 (0)7071- 920530 Fax: +49 (0)7071-9205311 | info@curevac.com | www.curevac.com | CureVac GmbH was founded as a spin-off of the University of Tübingen and has very quickly become established as one of the leading manufacturers of nucleic acids for use as active ingredients in pharmaceutical and therapeutic applications. CureVac GmbH’s portfolio primarily includes three products. 1) Modified and non-modified short (oligo-) RNA molecules are synthesised chemically in accordance with customers’ wishes. 2) The firm also offers RNActive™, an ultra-pure and stabilised form of mRNA that enables tissue and cells to be transfixed effectively. 3) In accordance with customers’ wishes, CureVac can create cDNA libraries in copyright-protected RNActive™ vectors. | Dr. Ingmar Hoerr (ih@curevac.de) | 48 | CureVac has cGMP production facilities compliant with FDA and EMEA standards | New approach to in vivo tissue generation through RNA technology, with skin tissue as an example | ||
| TETEC® AG | Biotech | Medicine, Medical Technology, Regenerative Biology | Development of new methods for the treatment of complex damage to and disease of the human skeletal and locomotor system. | Reutlingen | Dr. med. Karl-Christoph Gaissmaier Dr. Stephan Rapp | 2000 | Tissue Engineering Technologies - Aktiengesellschaft zur Entwicklung und Herstellung von biologischem Gewebeersatz Aspenhaustrasse 25 72770 Reutlingen Germany Tel.: +49 (0)7121-514-8760 Fax: +49 (0)7121-514-8761 | info@tetec-ag.de | www.tetec-ag.de | TETEC was initially founded as a limited liability company (GmbH). In 2003, TETEC® was converted into a joint-stock company (AG). “TE” stands for tissue engineering and “TEC” for innovative technologies. TETEC AG holds a manufacturing permit in accordance with §13 Para.1 German Drug Law (AMG) for its autologous cartilage cell products NOVOCART, NOVOCART 3D and NOVOCART Disc. NOVOCART is an autologous chondrocyte preparation while NOVOCARD 3D is a combination of autologous cartilage cells and a bi-phasic, three-dimensional, collagen-based matrix. NOVOCART 3D is ideal for the biological reconstruction of articular cartilage defects. NOVOCART Disc is a high-quality, autologous cell preparation for the biological reconstruction of partially-damaged intervertebral discs following a slipped disc. ADCT (Autologous Disc Cell Transplantation; the transplantation of in chondrocytes from autologous disc tissue that have been cultured in vitro) is the only method that facilitates the biological reconstruction of partially-damaged disc tissue before widespread degeneration occurs. The cultured cartilage cells, isolated from the biopsy material, induce the desired biological reconstruction. | Dr. Stephan Rapp | 20 | The company operates in accordance with GMP standards | Therapeutic use of adult mesenchymal stem cells (MSC) for the replacement of cartilage/bone. Joint research project: Gelatin-based, smart biomaterials for cartilage regeneration | ||
| Gambro Dialysatoren GmbH | Medtech | Medicine, Medical Technology, Trade/Distribution | Dialysis technology | Hechingen | Dr. Heiko Zimmermann (CEO) | 1973 | Holger-Crafoord-Strasse 26 72379 Hechingen Tel.: +49 (0)7471-170 Fax: +49 (0)7471-171157 | info.germany@gambro.com | www.gambro.com | Gambro is a global group that specialises in dialysis technology, blood component technology and healthcare services. The joint-stock company, based in Sweden, is divided into Gambro Healthcare, Gambro Renal Products and Gambro BCT. It’s Hechingen office is one of the group’s production facilities operated by Gambro Renal Products, manufacturing dialysis machines, haemoperfusion cartridges, electrolyte concentrates and other medical items for single use. Hechingen is also home to the research and development centre for dialysis machines/membrane technology and the logistics and distribution centre for Germany, Switzerland, Austria and the Benelux countries. One of the branch offices of Gambro Dialysatoren GmbH, which is also located in Hechingen, solely produces catheters for use in dialysis. | Approx. 1500 | CE certificate as per EC guideline 93/42EEC, certificate compliant with ISO 13485, Certificate ISO 14001, basic certificate from the “Beruf + Familie” audit | New, molecularly-defined, MIF-based methods for extracorporal apheresis aimed at regenerating plasma in sepsis and SIRS. Antibacterial and biofunctional surfaces for extracorporal and cell therapy methods. | |||
| Mediagnost GmbH | Biotech | Medicine, Nutrigenomics, Diagnostics | Testing systems for numerous applications in the field of infection diagnosis, endocrinology and food analysis; the production of antibodies, proteins and viruses | Reutlingen | Dr. Angelika Haage (Managing Director) | 1985 | Aspenhaustrasse 25 72770 Reutlingen Germany Tel.: +49 (0)7121-51484-0 Fax: +49 (0)7121-51484-10 | info@mediagnost.de | www.mediagnost.de | Mediagnost GmbH was founded in 1985 in Tübingen and is now based in the Tübingen-Reutlingen technology park. Mediagnost produces antibodies, proteins and viruses in accordance with GMT guidelines. The testing systems focus on infectious diseases such as hepatitis A/C, enteroviruses, HIV and the diagnosis of Pseudomonas aeruginosa. The firm’s portfolio also includes testing systems for the qualitative demonstration of genetically-modified foods and contamination of food, along with immunoassays used in endocrinology. | Dr. Angelika Haage | Production in accordance with GLP and GMP guidelines as decreed by the German Drug Law (AMG) and the Act on Medical Devices (MPG). Quality management system certified according to ISO 9001:2000. | AgeQuant – development of a multi-dimensional testing system for the quantitative determination of parameters relevant to regenerative biology in ageing humans. | |||
| BioTeSys GmbH | Biotech | Services, Drug Development, Diagnostics | Analysis of the biological function of active ingredients | Esslingen | Dr. Jürgen Bernhardt (CEO) Dr. Karin Engelhart (CSO) Consuelo Gallardo (COO) | 1999 | Schelztorstrasse 54-56 73728 Esslingen Germany Tel.: +49 (0)711-31057150 Fax: +49 (0)711-31057151 | bts@biotesys.de | www.biotesys.de | BioTeSys was founded in 1999 as a spin-off of the Institute of Biological Chemistry and Nutritional Science at the University of Hohenheim and has moved to the LSC (Life Science Centre) in Esslingen. BioTeSys has established and expanded three areas of expertise for its commercial activities. These include: Analysis, whose techniques are deployed either independently or in concert with others; Cell and Tissue Culture, complete with its associated testing options and Services for Clinical Trials (applications, monitoring, coordination etc.). The company’s own research focuses primarily on micronutrients and their enrichment for regenerating biological systems. BioTeSys uses nanoparticles as a new and smart means of transport for encapsulating active ingredients and addressing them so that they exert their effect directly on the target organ. This reduces the quantity of active ingredient in the body and avoids putting strain on the organism as a whole. Commissioned by Pascoe Pharmazeutische Präparate GmbH, BioTeSys developed a kit for determining micronutrients. This kit currently enables the presence of vitamin C, the E vitamins, ß-carotene and lycopene to be detected in swabs taken from oral mucosal tissue. | Dr. Jürgen Bernhardt (j.bernhardt@biotesys.de) | 14 | Nutritargeting: highly-selective enrichment strategies for the regeneration of biological systems | |||
| Retina Implant AG | Medtech | Medical Technology, Regenerative Biology, Information Technology | Development and marketing of a sub-retinal implant | Reutlingen | Walter-G. Wrobel (Chairman and CEO) Reinhard Rubow (CFO) | 2003 | Technologiepark Tübingen-Reutlingen Gerhard-Kindler-Strasse 8 72770 Reutlingen Germany Tel: +49 (0)7121-364030 Fax: +49 (0)7121-36403115 | www.retina-implant.de | Retina Implant AG is a medical technology start-up company founded in 2003 and built on the results of a research project that has been ongoing since 1996 and which involves numerous German university hospitals and research institutions, including the University Eye Hospital in Tübingen, the NMI Natural and Medical Institute in Reutlingen, the Institute of Microelectronics in Stuttgart, die University Eye Hospital and Ophthalmology Outpatients’ Department in Regensburg and the Institute of Physical Electronics at the University of Stuttgart. The company was converted into a corporation (AG=Aktiengesellschaft) in July 2007. Retina Implant’s scientists primarily focus on patients with retinitis pigmentosa, a hereditary condition that can lead to complete blindness in just a few years. Retina Implant is developing retinal implants that are intended to restore vision after blindness has occurred. The development work focuses on an active, sub-retinal silicon chip with tiny photo-sensors which control an electronic switch enabling the nerve cells of the retina to be supplied with more or less electrical stimulation, depending on the brightness. These send impulses via the optic nerve to the brain which can then generate a picture from these signals. Only recently, 2 blind patients were implanted the sub-retinal chip. Since undergoing surgery, both patients are able to make out shapes. In April 2006, as part of a capital increase, Mediplan GmbH took around a 25% share in Retina Implant AG by investing Euro 7.5 million in an initial tranche. Mediplan has also committed to investing a further Euro 7.5 million in the company once CE accreditation has been gained, which is required before a medical product can be marketed in Europe. The newly acquired funding will enable Retina Implant to finance clinical trials and the cost of approving the chip for market until it achieves break-even. Retina Implant AG is hoping to launch a fully functional chip in about two years' time. An important step towards reaching this goal is the recent ISO certification of the company. | Walter-G. Wrobel | 10 | Long-term compatibility of functional electrical retina stimulation to restore sight. Qualitative and quantitative analysis of retinal changes following electrical stimulation in an organo-typical retina culture. | ||||
| JOTEC GmbH | Medtech | Medicine, Medical Technology, Process Engineering | Development and production of vessel prostheses and stenting systems | Hechingen | Thomas Bogenschütz, CEO | 2000 | Lotzenäcker 23 72379 Hechingen Germany Tel.: +49 (0)7471-9220 Fax: +49 (0)7471-922100 | info@jotec.net | www.jotec.net | Since 2000, the medical technology firm has been developing and producing various systems that can be used to treat vascular diseases. Its portfolio of products includes vessel prostheses made from ePTFE and polyester. Coating technologies involving collagen and heparin reduce the risk of thrombosis. The firm also supplies stents, stent prostheses and various insertion systems that are designed based on its experience of nitinol and catheter technologies. In the field of tissue engineering, JOTEC offers a patch made from a micro-porous collagen matrix and collagen membrane (Matricart) that helps in the creation of autologous cartilage implants. | 125 | In vivo endothelialisation of vessel prostheses through coating with DNA aptameres as catcher molecules for endothelial progenitor cells (EPC). | ||||
| novineon Healthcare Technology Partners GmbH | Biotech | Services, Nutrigenomics | Consulting and research in the field of healthcare technology | Tübingen | Prof. Marc O. Schurr (Managing Director) | 2001 | Dorfackerstrasse 26 72074 Tübingen Germany Tel.: +49 (0)7071-7704514 Fax: +49 (0)7071-763574 | info@novineon.com | www.novineon.com | novineon operates in all sectors of the healthcare industry. The consulting firm, with its international network, supports manufacturers and users of medical products and services in all aspects of development, trials and marketing. Its research activities – including both its own and commissioned research – focus on the development, trial and validation of new technologies in medicine and ranges from the development of concepts and prototyping to the medical trials of prototypes and validation of the new product. The company also holds shares in newcomers to the industry and supports them as they turn their technologies into marketable products. | Joint research project: Tissue engineering with entodermal stem cells and the development of endoscopic technologies for the removal of such cells from the colon | |||||
| SOURCON-PADENA GmbH & Co. KG | Biotech | Services, Ecology/Environment, Trade/Distribution | Developing, manufacturing and marketing biological active agents to protect agricultural crops from pests. | Tübingen | Hilke Arndt (CEO and founder) | 2000 | Hechinger Strasse 262 72072 Tübingen Germany Tel.: +49 (0)7071-97552-0 Fax: +49 (0)7071-97552-50 | info@sourcon-padena.de | www.sourcon-padena.de | SOURCON-PADENA was founded in April 2000 as a joint-stock company (AG) from two private enterprises. The two original companies were spin-offs from the Universities of Stuttgart-Hohenheim and Tübingen. In May 2001, SOURCON-PADENA won Buck Chemie GmbH of Herrenberg, Germany, as a partner by acquiring a minority stake in the company. SOURCON-Padena's core expertise lies in the isolation, cultivation and extraction of micro-organisms as delivery media for active substances. Using quality control procedures in accordance with HPLC-MS, the company supplies high-quality extracts to search for active substances that are free from disrupting factors and are proven to contain new substances that were previously not accessible through conventional methods. The company also specialises in fermentation technologies and offers these at pilot-plant scale up to 200 litres (S1). The company's PRORADIX® plant strengthener, which effectively protects agricultural crops against pests in harmony with nature, is already marketed in the agricultural sector. The active agent is a natural soil bacterium that surrounds the roots of agricultural crops and can function from there without interfering with the ecosystem in the long term. | Associated project NAPRAS; Development of new agents against biofilm formation on regenerative and synthetic tissue implants; Subproject 1: Isolation and identification of the active agents | |||||
| Multi Channel Systems MCS GmbH | Biotech | Laboratory Techniques | Electrophysiology, automation | Reutlingen | Karl-Heinz Boven (Managing Director) Andreas Möller (Managing Director) | 1996 | Aspenhaustrasse 21 72770 Reutlingen Germany Tel: +49 (0)7121-909250 Fax: +49 (0)7121-9092511 | info@multichannelsystems.com | www.multichannelsystems.com | Multi Channel Systems MCS GmbH was founded in 1996 and is based in the Reutlingen/Tübingen Science and Technology Park. Its focus lies on the development of measuring instruments and technical accessories in the context of electrophysiology for university-based research and the pharmaceutical industry. MCS products automate laborious measuring methods and analyses. Three product lines demonstrate Multi Channel Systems’ core areas of expertise: in vitro and in vivo systems for the derivation of extracellular activities of excitable cells; the Robocyte, a fully-automatic “two-electrode voltage clamp (TEVC)” system for oocytes of the African clawed frog Xenopus laevis and its latest development, the QT Screen – an automated system for tests on the potential extension of the QT interval. This is a key instrument for safety pharmacology applications in the development of new medications. The goal is always to develop intelligent and convenient solutions that combine maximum functionality with ease of use. | Karl-Heinz Boven | 16 | Development of a biotechnology platform for electrophysiological tissue assays for the investigation of active agents in conditions that are as similar as possible to in vivo | |||
| PANATecs GmbH | Biotech | Services, Medicine, Nutrigenomics, Diagnostics | Provision of bioanalytical services, particularly mass spectrometry-based, for the pharmaceutical, foodstuffs and animal feed industries. Manufacture and sale of bioanalytical substances for research (e.g. peptides, antibodies, marker reagents etc.). | Tübingen | Dr. Thomas Flad, Pharmacist (CSO) Alexander Cansier (COO) | 2004 | Ob dem Himmelreich 7 72074 Tübingen Germany Tel.: +49 (0)7071-29720-93, -94 and -95 Fax: + 49 (0)7071-294445 | info@panatecs.com | www.panatecs.com | PANATecs GmbH was founded in 2004 as a spin-off of the University of Tübingen. Its founding partners are Prof. Claudia Müller (Transplantation Immunology and Immunohaematology Section, “Medizinische Klinik und Poliklinik”, Dept. II), Prof. Gerhard A. Müller (Nephrology & Rheumatology Department, Centre for Internal Medicine, Georg August University, Göttingen), Dr. Hubert Kalbacher (University of Tübingen, Physiological Chemistry Institute (PCI), Medical and Scientific Research Centre, University of Tübingen) and the two Managing Directors Dr. Thomas Flad and Alexander Cansier. In addition to the production of bioanalytical products and the conducting of specialist analyses, PANATecs GmbH also carries out its own research projects. In collaboration with major partners, the firm handles projects from the field of clinical mass spectrometry. The aim of these research activities is to develop new, mass spectrometry-based diagnostic methods for the early detection of autoimmune and cancer-related diseases. | Alexander Cansier | 12 | Development of new tests for the molecular diagnosis of rheumatoid arthritis | |||
| Dr. Fenyves und Gut Deutschland GmbH | Medtech | Medical Technology, Diagnostics, Process Engineering | The development of diagnostic systems and data recording equipment; sleep diagnostics and sleep screening | Hechingen | Andreas Faulhaber (CEO) | 1973 | Lotzenäcker 9 72379 Hechingen Germany Tel.: +49 (0)7471-9374 0 Fax: +49 (0)7471-9374 30 | info@fg-deutschland.de | www.fg-deutschland.de | This company, founded over 30 years ago, develops and produces diagnostic systems for use in the fields of lung function analysis and sleep medicine. Its portfolio of products includes sleep screening systems for the diagnosis of sleep-related respiratory problems, endurance training equipment for the respiratory musculature (Spirotiger) and biosignal simulators. The company markets pneumotachographs (laminar flow elements, after Prof. Fleisch) which capture precise flow signals in the measurement of gas flows. One further area of focus includes stationary and portable data recording equipment (data loggers) for use in technical applications. | Andreas Faulhaber (CEO) | 5 | ISO 9003 | |||
| Fraunhofer-Institut für Grenzflächen- und Bioverfahrenstechnik IGB | Institute | Services, Medicine, Chemistry, Process Engineering | The creation of solutions for business and public clients in the fields of health, the environment and technology | Stuttgart | Prof. Dr. Thomas Hirth (Institute Director) | 1952 | Nobelstrasse 12 70569 Stuttgart Germany Tel.: +49 (0)711-9704001 Fax: +49 (0)711-9704200 | info@igb.fraunhofer.de | www.igb.fraunhofer.de | IGB’s roots go back to 1952, the year in which the Institute of Surface Physics and Chemistry was founded. The Institute was taken over in 1962 by the Fraunhofer Society. The Institute was given its present name in 1976, coinciding with the creation of the research fields involving bioprocess technology and membrane technology. The Fraunhofer IGB is one of six Fraunhofer institutes in Stuttgart, the Fraunhofer Society’s largest location. The IGB’s main areas of expertise include surface technology, membrane technology, biotechnology, cell system technology and bioprocess technology. The IGB offers its clients full-service solutions, ranging from market analysis and research to ready-to-use development. The scientists working at the IGB focus on various disciplines – from physics, chemistry, biology and molecular biology to engineering-related sciences. Their goal is to translate biological and biochemical problems and challenges in product preparation and environmental technology into commercially-attractive and environmentally-friendly processes and products. The IGB’s core areas of research are handled in four divisions, each focusing on different areas of application or business. 1) The “Molecular Substances for Pharmaceuticals and Chemical Industries” division focuses primarily on the development of therapeutic proteins and target screening, diagnostic methods using biochips and diagnostic agents, biocatalysis and enzyme screening, fermentation, downstream processing and scale-up production. The second division focuses on the development of 3-dimensional, organoid cell structures as test systems, tissue engineering and manufacturing based on GMP guidelines. In the “Functional Surfaces and Membranes” division, the scientists primarily work on surface-dominated polymers, biomaterials and biomimetic surfaces, together with the design of new membranes. The Fraunhofer IGB’s fourth division is devoted to biotechnical environmental rehabilitation, the recycling of organic waste, waste water purification and water management and the regenerative production of materials using microalgae. In addition to this purely R&D-based activity, the Fraunhofer IGB also offers services in various sectors such as analysis, molecular biology, cell biology and commissioned research into cell therapy agents based on GMP. | Dr. Claudia Vorbeck (claudia.vorbeck@igb.fraunhofer.de) | 140 | Accreditation to DIN EN ISO/IEC 17025 for HPCL, IC, GPC, GC and GC/MS, ESCA; GMP unit and manufacturing permit for autologous chondrocyte transplants (others have been applied for). | |||
| Greiner Bio-One GmbH | Biotech | Laboratory Techniques | Development of laboratory products and synthetic consumables for the life sciences sector | Frickenhausen | Dr. Axel Greiner, Executive Director Boris Greiner MBA, Executive Director Heinz Schmid, Managing Director of Greiner Bio-One GmbH, Germany | 1868/1963 | Maybachstrasse 2 72636 Frickenhausen Germany Tel.: +49 (0)7022-9480 Fax: +49 (0)7022-948514 | info@de.gbo.com | www.gbo.com | Carl Albert Greiner founded the firm in 1868, which originally started out producing corks. Later, Greiner specialised in the processing of synthetics. Greiner Bio-One GmbH in Frickenhausen, which belongs to the BioScience division of the Greiner Bio-One International AG holding company, is responsible for the manufacture of the firm’s laboratory products. The portfolio includes diagnostic and analytical methods, HTS products (High-Throughput Screening) for the screening of pharmaceutical active agents, specialist vessels for tissue culture and products used in the context of biochip technology (PapilloCheck® for the early detection of cervical cancer, ParoCheck® for the detection of periodontal pathogens, CarnoCheck® for the detection of the DNA of eight animal species in food, CytoCheck® for the quality assurance in the biopharmaceutical industry). | Tobias Rigling (Marketing) | 6000 (worldwide), 1100 (BioScience + Preanalytics), 400 (BioScience) | DIN EN ISO 9001:2000 ISO 13485:2003 | |||
| STRATEC Biomedical Systems AG | Biotech | Services, Information Technology, Process Engineering | STRATEC Biomedical Systems AG plans, develops and produces fully-automatic analysis systems for partners from the field of clinical diagnostics and life sciences using its own, patent-protected technologies. | Birkenfeld | Hermann Leistner (Board Chairman) Marcus Wolfinger (CFO) Bernd M. Steidle (Director of Sales and Marketing) | 1979 | Gewerbestrasse 37 75217 Birkenfeld Germany Tel.: +49 (0)7082-79160 Fax: +49 (0)7082-7916999 | info@stratec-biomedical.de | www.stratec-biomedical.de | Founded in 1979 as STRATEC Elektronik GmbH, the company focused in 1994 on the core areas of OEM (Original Equipment Manufacturer) development and the production of integrated solutions for international manufacturers of diagnostic agents. STRATEC products have enjoyed success especially in the growth sectors of laboratory diagnostics and life sciences. Based on its existing product platforms, STRATEC develops innovative, customer-focused products with an effective cost structure and within a period of 18 to 36 months. STRATEC offers a first-rate full service and provides its entire range of instruments from a single source, drawing on a broadly-based pool of technologies including: liquid handling systems, software, robotics and detection modules, process validation, documentation services and approval services. New technologies are continuously being developed in the field of diagnostics and life sciences accompanied by changes in regulations so that processes must constantly be adapted to their specific environment. STRATEC meets all these challenges by supporting its customers’ instrumentation activities in the field of project management, hardware and software engineering, verification and production. With experience spanning over 25 years and an in-depth knowledge of technology and the regulations governing it, STRATEC offers its partners valuable support in all phases of the system life cycle. STRATEC’s development and production facilities are based on its own, patent-protected technologies and focus on integrated solutions. The company’s partners are skilled in market knowledge and specific reagent expertise while STRATEC provides expertise and application know-how in natural and engineering sciences as well as in automation and application software. | Bernd M. Steidle (b.steidle@stratec-biomedical.de) | 183 | DIN EN ISO 9001, DIN EN ISO 13485, FDA-registered , CSA/UL-registered | |||
| biosyn Arzneimittel GmbH | Biotech | Drug Development, Medicine, Nutrigenomics, Diagnostics | biosyn Arzneimittel GmbH was founded 1984 and is one of the first biotechnology companies. As a research oriented company biosyn focuses on oncology and intensiv care medicine. | Fellbach | Dr. Thomas Stiefel (Managing Director) Ortwin Kottwitz (Managing Director) | 1984 | Schorndorfer Strasse 32 70734 Fellbach Germany Tel: +49 (0)711-5753200 Fax: +49 (0)711-5753299 | info@biosyn.de | www.biosyn.de | biosyn Arzneimittel GmbH has specialised primarily in the fields of oncology and intensive care medicine biosyn currently offers around 30 drugs approved in 15 countries. biosyn's develpoment strategy is based on biologic molecules and trace elements that have proven efficacy with few side effects. Hemocanin based products like IMMUCOTHEL® or VACMUNE® are used in bladder cancer or as carriers for therapeutic vaccines. Selenium compounds like Sodiumselenite (selenase®) are used in sepsis patients to reduce mortality. In a double-blind, prospective study (SIC) study it could be demonstrated that high dose sodium selenite reduces the mortality rate for sepsis patients. The mortality rate among patients who were administered the drug was 42% as opposed to 57% for the control group. High dose selenium leads to a significant reduction (14,3%) in the mortality rate even in cases of severe sepsis such as septic shock. biosyn Vertriebs AG in Balzers, Liechtenstein and the biosyn Corporation in Carlsbad, California, USA, are subsidiaries of biosyn. biosyn also has a scientific office in Austria. | Approx. 80 | biosyn’s laboratories in Fellbach are GMP-certified | ||||
| ERBE Elektromedizin GmbH | Medtech | Medicine, Medical Technology, Trade/Distribution, Process Engineering | Development, manufacturing and sale of systems for electrosurgery, cryosurgery and physiotherapy. | Tübingen | Christian O. Erbe (CEO) Reiner Thede (CEO) | 1847 | Waldhörnlestrasse 17 72072 Tübingen Germany Tel.: +49 (0)7071-7550 Fax: +49 (0)7071-755179 | sales@erbe-med.de | www.erbe-med.de | ERBE Elektromedizin GmbH was formed from the workshop founded by Christian Heinrich Erbe in Tübingen 1847. ERBE develops and produces systems for electro-, cryo- and ophthalmological surgery and physiotherapy. It also markets a water jet-based surgery system. Its portfolio is geared towards surgical installations in all manner of disciplines within hospitals and specialist physicians’ practices both within Germany and abroad. The company has subsidiaries across Europe and in the USA, representatives in China and Russia and trade agencies worldwide. | 500 (worldwide), 400 (Germany), 350 (Tübingen) | QM system: ISO 9001, ISO 13485 Appendix II of Guideline 93/42/EEC; Licences: Conformity assessments and permits as decreed by EC guideline 93/42/EEC | ||||
| AnDiaTec GmbH & Co. KG | Medtech | Medicine, Medical Technology, Diagnostics | Innovative in vitro diagnostics for human and veterinary medicine, together with the food and environmental sector | Kornwestheim | Dr. Johannes Kehle (CEO) | 2003 | Leibnizstr. 11 70806 Kornwestheim Germany Tel.: +49 (0)7154-806 23-0 Fax: ++49 (0)7154-806 23-24 | info@andiatec.com | www.andiatec.com | AnDiaTec was founded by Dr. Johannes Kehle and Dr. Christoph Metzger-Boddien. AnDiaTec GmbH & Co. KG’s core activities focus on the development, manufacture and sale of in vitro diagnostic tools. The products marketed include ParaTub® and LactoScan®. ParaTub® is currently the only high-throughput detection method for Mycobacterium paratuberculosis (MAP), the pathogen responsible for incurable paratuberculosis in cattle. MAP causes major economic damage and is also linked to the inflammatory bowel condition called Crohn’s disease in humans. LactoScan® is a simple and rapid test for reliably detecting lactose intolerance in humans. It is likely that more than 10 million people in Germany are affected by lactose intolerance, a disease that, in the form of primary lactose intolerance, has genetic causes and can lead to under-supplies of lactase between the ages of 6 and 20 and subsequently lead to symptoms typical of the disease. AnDiaTec GmbH & Co. KG is also an adviser to the WHO in the context of a diagnostic project for enteroviruses in India. | The laboratory is accredited in accordance with DIN EN ISO IEC 17025 and 15189 | |||||
| Consic Software Engineering | Biotech | Information Technology | Software development | Kusterdingen | Managing Directors: Stefan Heymann Frank-P. Schänzlin | 2003 | Lustnauer Strasse 18 72127 Kusterdingen Germany Tel.: +49 (0)7071-689639 | info@consic.de | www.consic.de | Consic develops software designed to support quality management and production in the manufacturing, automotive and biotechnology industries. Consic software solutions can be tailored to the needs of individual customers or supplied as standard software products such as METER and PMM. METER software is used for the quality control of series parts and PMM has been developed for monitoring test instruments in quality management. As well as software, Consic also offers services such as customised add-ons, integration, training and support. | DIN/EN/ISO 9001:2000 | |||||
| JOLINE GmbH & Co. KG | Medtech | Medical Technology | Production of catheters for use in dialysis | Hechingen | Wilfried Hermes, Head of Sales & Marketing Karl-Heinz Klotz, Head of Development Dr. Anselm Steegers, Head of Quality Management Thomas Müller, Head of Production | 1999 | Neue Rottenburger Strasse 50 72379 Hechingen Germany Tel.: +49 (0)7471-98810 Fax: +49 (0)7471-9881111 | info@joline.net | www.joline.de | The company, founded in 1999 by Lars Sunnanväder, specialises in the production of various catheters for use in dialysis and sells its products worldwide. Single-lumen, double-lumen and triple-lumen catheters are manufactured for use in acute dialysis. For chronic dialysis, the company produces single- and double-lumen silicon catheters in order to ensure maximum biocompatibility. | CE mark, ISO certification | |||||
| Friedrich Bosch Medizintechnik GmbH + Co. KG | Medtech | Medical Technology, Process Engineering | Manufacture of blood pressure monitoring equipment and accessories | Bisingen | 1924 | Hohenlaienstrasse 30 72406 Bisingen Germany Tel.: +49 (0)7476-3554 Fax: +49 (0)7476-3556 | jb@fbosch.de | www.fbosch.de | Friedrich Bosch Medizintechnik GmbH + Co. KG manufactures medical equipment and accessories relating to blood pressure monitoring for hospitals and doctors worldwide. Its range of products include sphygmomanometers for doctors and for self-measurement, pulse meters, tourniquets and cuffs of various designs, together with other diagnostic equipment such as laryngoscopes and otoscopes. | CE certificate, i.e. certified according to DIN ISO 9001 and EN 46001 | ||||||
| SCHOBER medicare GmbH | Medtech | Medical Technology | Development, production and sale of magnetic field therapy systems | Hechingen | Eberhard Schober (CEO) | Zu den Linden 3 72379 Hechingen Germany Tel.: +49 (0)7471-617611 Fax: +49 (0)7471-617612 | info@schober-medicare.de | www.schober-medicare.de | Schober’s equipment system for electromagnetic field therapy comprises a control unit and an applicator which generates a pulsing magnetic field. The applicators take the form of mats, cushions and/or cuffs, thereby facilitating local or full-body treatment. The numerous areas of application include inflammatory and degenerative complaints of the musculoskeletal system, oxygen enrichment of the lungs and metabolic disorders. The firm’s pulsing magnetic field resonance systems can be used in both human and veterinary medicine. | Certified in accordance with Appendix II, Section 3 of the Guideline 93/42 EEC; CE mark | ||||||
| npi electronic GmbH | Biotech | Drug Development, Medicine, Laboratory Techniques, Process Engineering | Electronic measuring instruments for the life sciences sector, drug-screening systems | Tamm | Hannelore Polder Hans Reiner Polder (M.Sc.EE) | 1989 | Hauptstrasse 96 71732 Tamm Germany Tel.: +49(0)7141-9730230 Fax: +49(0)7141-9730240 | sales@npielectronic.com | www.npielectronic.com | Hans Reiner Polder founded npi in 1989 based on the method he developed to improve the measurement of intracellular signals. Using this newly-developed enhancement system, it was possible to improve the resolution capabilities of existing measuring systems. npi currently has a wide portfolio of products for recording bio-electrical signals. npi develops and sells numerous systems for use in fundamental medical, biological and drug research, such as voltage and patch clamp amplifiers, intra- and extracellular amplifiers, micromanipulators etc. The firm also offers products for drug screening and laboratory automation. npi electronic is a member of the Electrophysiology Innovation Partnership network. | Hans Reiner Polder | 5 | ||||
| Synovo GmbH | Biotech | Services, Drug Development, Medicine | Testing methods for choosing drug candidates | Tübingen | Dr. Michael Burnet (CEO) | Paul-Ehrlich-Strasse 15 72076 Tübingen Germany Tel.: +49 (0)7071-964325 Fax +49 (0)7071-964326 | contact@synovo.com | www.synovo.com | Synovo GmbH is a pharmaceutical research company that offers services in the fields of synthetic chemistry, pharmacology, cell engineering and peptide modification. The company’s focus lies in providing various testing methods and models – ideally using human cells, proteins or systems – for the selection of drug candidates with improved properties in terms of absorption, distribution, metabolism and elimination (ADME or DMPK). On behalf of customers from the pharmaceutical industry, Synovo is involved in projects investigating anti-inflammatory and immuno-suppressive drug optimisation and the improvement of existing technologies used for the development of new drugs from proteins and nucleic acids. This work is carried out in collaboration with public-sector laboratories. | Dr. Michael Burnet | 20 | |||||
| Translumina GmbH | Medtech | Medicine, Medical Technology, Process Engineering | International company for medical technology focussing on drug-eluting stent systems | Hechingen | Lars Sunnanväder (Managing Director) | 2000 | Marketing & Sales Steinsdorfstraße 8 80538 München Germany Tel.: +49 (0)89-210289-0 Fax: +49 (0)89-210289-29 Production Neue Rottenburger Straße 50 72379 Hechingen Germany Tel.: +49 (0)7471-9894-0 Fax: +49 (0)7471-9894-380 | info@translumina.de | www.translumina.de | Translumina GmbH was established in 2000 and since then has developed into a leading company in the production and development of innovative and biocompatible stent coatings. Translumina has developed a coating system (YUKON®DES Drug Eluting Stent) and the Stent Coating Machine (SCM) for cardiac stents (vessel wall supports), which allow doctors to apply a customised medication coating to a stent, which is then inserted into the coronary vessels. The coating prevents occlusion and restenosis of the vessel. The active substance can be applied to the stent without the need for additional polymers. | 40 | |||||
| LAZ Prof. Dr. H. Hamacher - Laboratorium für Arzneimittelprüfung und Zulassungsberatung | Biotech | Services | Quality testing of pharmaceutical source materials, finished products and packaging materials. Development and validation of testing methods. Stability analyses. | Tübingen | 1984 | Dischinger Weg 15 72070 Tübingen Germany Tel.: +49 (0)7071-791163 Fax: +49 (0)7071-791598 | LAZ-Prof.Hamacher@t-online.de | www.laz-labor.de | With over 20 years of experience, the Laboratory for Testing Medicinal Products and Registration Advice (LAZ) is a pioneer in the area of pharmaco-analytical services and has built up exceptional specialist and advisory know-how in the development and registration of medical products. Its portfolio of analytical services includes the development and validation of testing methods, the implementation of quality control measures, compatibility and stability studies for medical products, the determination of residues, the characterization/structural analysis of impurities, microbiology and bioanalytics. All services are provided in strict accordance with current national and international regulatory requirements and under GMP-compliant conditions. The consultancy services of the LAZ cover all aspects of quality assurance related to the development and registration of medical products, the creation and appraisal of documentation and the management of regulatory procedures. | 11 | ||||||
| Agenolab GmbH & Co. KG | Biotech | Services, Regenerative Biology | Speciality laboratory for bioanalytics and cell culture technology Provider of contract services and developments | Stuttgart | Dr. Andreas Greither | Kesselstrasse 17 70327 Stuttgart-Wangen Tel.: +49 (0)711-3513847 Fax: +49 (0)711-3513839 | info@agenolab.de | www.agenolab.de | Young, innovative biotechnology & life sciences company offering microbiology and molecular biology applications, tissue engineering, GMP production (§ 15 AMG), quality assurance, histology and oncology. Provider of contract services and developments using a laboratory with state-of-the-art equipment. | 10 | ||||||
| Anoxymer GmbH | Biotech | Nutrigenomics | Health-giving plant substances for functional food and cosmeceuticals | Esslingen | Wolfgang Neldner (CEO) Dr. Karim Balan (CEO) Dr. Dietrich Paper (Director of R&D) | 2000 | Schelztorstrasse 54-56 D-73728 Esslingen Germany Tel.: +49 (0)711-90121090 Fax: +49 (0)711-90121099 | info@anoxymer.info | www.anoxymer.com | Anoxymer was founded at the end of 2000 and was headquartered at the Kompetenzzentrum für nachwachsende Rohstoffe (Competence Centre for Sustainable Raw Materials) in Straubing (Bavaria) until the end of 2005. Based in the Lifescience Center Esslingen since the start of 2006, the company specialises in research and development into new and innovative health ingredients from herbs, vegetables and fruits and uses these to produce standardised, highly water-soluble plant extracts with proven health benefits. Anoxymer markets these extracts as ingredients for foods (functional foods) and cosmetics (cosmeceuticals), and in the form of capsules/tablets as dietary supplements. Screening for bioactive substances that have a positive effect on health has already led to the discovery of new substance classes of oligosaccharides of plant origin exhibiting different types of physiological activity (Anoxymins®). In addition to their antioxidant character (radical scavenging activity), the health-giving properties of individual secondary plant substances lie in their immune-strengthening antiangiogenic and/or anti-inflammatory activity. In addition to the isolation of bioactive substances accompanying the biotest, and their biological and chemical standardisation, the company's proprietary and interlinked in-vitro and in-vivo test systems (CAM assays) not only enable Anoxymer to demonstrate the effectiveness of the substances, but also to identify potential toxicities and side-effects in good time. Health-giving extracts (Planox®) from various plants for anti-ageing and joint health have already been developed. The company has worked with cooperation partners from the foodstuffs and cosmetics industries to adapt these to their specific technological requirements for use in various foodstuffs or cosmetic products. Anoxymer also has further bioactive natural substances for digestion, diabetes and skincare in its product pipeline. Anoxymer enables its customers to explore new pricing and design opportunities through added-value products. The scientifically proven data relating to the functional and health properties of the standardised plant extracts and enriched foodstuffs is corroborated by test studies so that, in the future, there will be more concrete evidence on the health benefits, which can also be used for advertising purposes. | Wolfgang Neldner (wneldner@anoxymer.com) | |||||
| DataPhysics Instruments GmbH | Biotech | Chemistry, Laboratory Techniques | Innovations for surface chemistry | Filderstadt | Torsten Holz Horst Rau | 1997 | Raiffeisenstrasse 34 70794 Filderstadt Germany Tel: +49 (0)711-7705560 Fax: +49 (0)711-77055699 | info@dataphysics.com | www.dataphysics.de | DataPhysics Instruments GmbH’s customers primarily include scientific institutions and research organisations. The company develops new measuring instruments and systems for the measurement of surface chemistry properties. DataPhysics products are designed to offer a long service life, precise engineering and maximum measuring accuracy. DataPhysics processes samples for the research and development of applications in its customers’ fields of activity. The firm develops solution proposals for complex, application technology problems. DataPhysics also offers training courses and workshops. Topics include the theoretical principles of surface chemistry, application-specific information on the use of measuring instruments and interpretation of measuring results, how to use the instruments, customer training and equipment training for users. | Torsten Holz (t.holz@dataphysics.de) | |||||
| Inmedea GmbH | Biotech | Medical Technology, Imaging, Information Technology | Development of a medical training programme | Reutlingen | Angelika Schäfer | 2006 | Gerhard-Kindler-Str. 6 72770 Reutlingen Tel: +49 (0) 7121-12706-0 Fax +49 (0) 7121-12706-20 | info@inmedea.com | www.inmedea.com, www.prometheus.uni-tuebingen.de | Inmedea GmbH is currently developing Prometheus, a teaching and training system that offers a realistic hospital simulation. The virtual hospital features various departments, each with typical patients, and a virtual multimedia library. The library includes a large collection of texts, tutorials, training programmes and reference works and offers a platform for acquiring theoretical knowledge, which is then applied in the virtual clinic and translated into expertise for use in real-life scenarios. The Prometheus project was funded up to 2003 as part of the German Federal Ministry of Education and Research (BMBF) "New Media in Education" initiative. The idea and concept behind the solution were developed by a working group from the Department of Neuroradiology at the University of Tübingen headed by Professor Voigt. | Angelika Schäfer, MD with responsibility for student learning; Franz Gerstheimer, MD with responsibility for CME | |||||
| Subitec GmbH | Biotech | Ecology/Environment | Development and manufacture of sustainable bioproducts made from microalgae | Stuttgart | Dr. Peter Ripplinger (Managing Director) | 2000 | Nobelstrasse 12 70569 Stuttgart Germany Tel.: +49 (0)711-970-4210 Fax. +49 (0)711-970-4200 | www.subitec.com | SUBITEC was founded as a spin-off in 2000 by scientists from the Fraunhofer Institute for Interfacial Engineering and Biotechnology (IGB). The materials’ photosynthetic production takes place in closed bioreactors that must be kept sterile. These bioreactors are currently land-based, but will in future also be water-based. SUBITEC GmbH offers a flat panel airlift reactor (FPA) that satisfies the requirements on the commercial mass production of microalgae outdoors. The FPA reactor works on the principle of the airlift loop reactor and, thanks to a low layer density and targeted flow in the reactor over static mixers, achieves the ideal light supply to all algal cells. The types of algae used include: chlorella vulgaris, isochrysis aff. galbana (clone t. iso), haematococcus pluvialis and phaeodactylum triconutum. | Prof. Walter Trösch (walter.troesch@igb.fhg.de) | ||||||
| AppliedSensor GmbH | Biotech | Diagnostics, Laboratory Techniques, Process Engineering | Sensors and sensor systems, including sensors for CO, NO2, CH 4, H2 and volatile organic compounds | Reutlingen | Dr. Robert Straubinger (Managing Director, CEO) Henrik Kennås (CFO) Thomas D. Aiken (Manager Marketing and Sales) Per Holmberg (Manager Module Development) Jürgen Kappler (Manager Sensor Component Development) Heiko Ulmer (Manager Application Support MOS) | Gerhard Kindler Str. 8 72770 Reutlingen Germany Tel.: +49 (0)7121-514860 Fax: +49 (0)7121-5148629 | robert.straubinger@appliedsensor.com | www.appliedsensor.com | AppliedSensor was formed in 2000 from the merger of NST (Nordic Sensor Technologies, a spin-off of the University of Linköping in Sweden) and MoTech (a spin-off of the University of Tübingen). Collaboration between the Universities of Linköping and Tübingen in the field of sensor technologies had been ongoing since 1972. AppliedSensor currently has offices in Linköping (the headquarters in Sweden), New Jersey (USA) and Reutlingen. As the name suggests, the firm’s main area of focus lies in the development of sensors and sensor systems, gas detectors based on metal oxide semi-conductor systems (MOS), which are used particularly in the detection of carbon monoxide and nitrogen dioxide, field effect sensors for hydrogen and ammonia and QMB sensors for determining the presence of volatile organic compounds. | Dr. Robert Straubinger (robert.straubinger@appliedsensor.com) | ||||||
| Hohenstein Institutes Bönnigheim | Institute | Services, Education | Contract research, testing, certification and consulting | Bönnigheim | Dr. Stefan Mecheels (Management) | Castle of Hohenstein 74537 Bönnigheim Tel.: +49(0)7143-2710 Fax: +49(0)7143-27151 | info@hohenstein.de | www.hohenstein.de | The Hohenstein Institutes are internationally recognised research and service centres. Companies and businesses along the entire textile chain, and in numerous other associated areas, benefit from the skills of the Hohenstein experts in research, development, testing, consulting, certification and all types of training. The core competences of the Hohenheim Institute of Hygiene and Biotechnology include: * hygiene and microbiological investigations (hygiene management) * safety testing (skin compatibility) * activity testing (antimicrobial surfaces) * efficacy testing (transfer of cosmetically and medically active substances, wound dressings) | Dr. Dirk Höfer, Head of the Institute of Hygiene and Biotechnology (d.hoefer@hohenstein.de) | ||||||
| E-Flox GmbH | Biotech | Ecology/Environment, Process Engineering | Development and marketing of a burner for energy conversion processes based on the principle of flameless oxidation (FLOX) | Stuttgart | Dr. Roland Berger | 2005 | P.O. Box 1109 71264 Renningen Street address: Dornierstr. 14 71272 Renningen Tel.: +49 (0)7159 930895 Fax: +49 (0)7159 930896 Germany | berger@e-flox.de | www.e-flox.de | E-Flox GmbH was founded on 17 November 2005 with the aim of developing and marketing a burner for energy conversion processes based on the principle of flameless oxidation (FLOX). The company founders from the IVD (Institute of Process Engineering and Power Plant Technology) have joined forces with WS Wärmeprozesstechnik GmbH from Renningen, which has been manufacturing and selling ‘conventional’ FLOX burners for some time. The ‘new’ type of burner will increasingly be used in biomass applications. | ||||||
| Hain Lifescience GmbH | Biotech | Diagnostics, Trade/Distribution | Manufacturing diagnostic systems | Nehren | David Hain (CEO) Tobias Hain (CEO) Roman Tepperwien (Sales Manager) Michael Wirth (Marketing Manager) Dr. Stefan Kress (Production Manager) Dr. Vera Allerheiligen (R&D Manager) | 1986 | Hardwiesenstr. 1 72147 Nehren Germany Tel.: +49 (0)7473-94510 Fax: +49 (0)7473-945199 | info@hain-lifescience.de | www.hain-lifescience.de | The company started out as a partnership founded by brothers David and Tobias Hain that was initially limited to mail order. Following the development of new diagnostic tools, the company was restructured in 1989 to form Hain Diagnostika GmbH. In 2001, Hain Diagnostika GmbH merged with Advanced Diagnostic Systems GmbH (ADS) and was renamed Hain Lifescience GmbH in 2002. One of the base technologies established by Hain Lifescience is the DNA-STRIP® which, although comparable to DNA chips, is more cost-effective and accurate. The company also develops products for genotyping, dental, microbiological and molecular-biological diagnostic solutions, and swab and transport systems. | ||||||
| Hezinger Algaetec GmbH | Biotech | Trade/Distribution | Development, production and distribution of installations for the cultivation of microalgae on an industrial scale | Kornwestheim | Steffen Hezinger (CEO) Timo Enderle | 2007 | Max-Planck-Straße 1 70806 Kornwestheim Tel: +49 (0)7154 8208-80 Fax: +49 (0)7154 8208-88 | algaetec@hezinger.net | www.hezinger-algaetec.com | Hezinger Algaetec was founded in 2007 with the aim of developing and producing installations for the industrial cultivation of microalgae and distributing these worldwide. The company plans and supplies the entire production chain – from algae cultivation to biomass utilization – as a complete, customized system. The key components of the installations are the photobioreactors, which the company develops in-house. The premise of the procedure developed by Hezinger Algaetec is to utilize as little artificial energy (e.g. electricity) as possible in the system. The main source of energy for the bioreactors is natural sunlight, the use of which ensures that industrial algae cultivation is cost-effective, environmentally friendly and results in a positive energy balance. Hezinger Algaetec works closely with well-known biology, light engineering and planning specialists in order to ensure perfect results in the development and production of photobioreactors. | ||||||
| LEHNER GmbH SENSOR-SYSTEME | Biotech | Ecology/Environment, Information Technology, Process Engineering | Development of specific sensor systems | Kirchheim unter Teck | Rolf-Peter Lehner (Managing Director) | 1990 | Kruichling 31 73230 Kirchheim/Teck Germany Tel.: +49 (0)7021-97013-0 Fax. +49 (0)7021-97013-33 | info@lehner-gmbh.com | www.lehner-gmbh.com | Lehner GmbH Sensor-Systeme was founded in 1990 by Rolf-Peter Lehner. Its traditional focus is on printing processes in the graphic arts industry, but the company now also develops specific sensor systems geared to the requirements and challenges of other customer sectors, including biotech research institutes. For example, the company has joined forces with scientists from the Institute for Biology II at the University of Freiburg and other partners to develop and produce a modular measuring instrument for the continuous cultivation and analysis of biological material. | ||||||
| Nexxor GmbH | Biotech | Services, Information Technology | Knowledge-oriented information systems for the life sciences, pharmaceutical and biotechnology sectors | Stuttgart | Dr. Gerhard Weber Ralf Eilbracht Stefan Kesberg | 2008 | Vollmoellerstr. 11 70563 Stuttgart Tel.: +49 (0)711-91260466 Fax: +49 (0)711-91260468 | info@nexxor.de | www.nexxor.de | Nexxor GmbH develops so-called “knowledge-oriented information systems” using its proprietary topicWorks technology, which is based on a family of semantic ISO standards. The company, which was established in 2008 by two bioinformaticians and an ecologist, designs software solutions specifically aimed at clients in the life sciences, pharmaceutical and biotechnology sectors. The software systems developed by Nexxor do not just focus on data and documents, but are also able to represent the meaning and context of database content in a flexible and meaningful way, thus making the knowledge of individual members of a cooperative project accessible to all. In addition, the software systems enable independent data sources to be linked. The technology can for example be used for the administration of a broad range of project data generated by medical, pharmacological, agricultural or ecological studies, but also for substance collections or drug information systems, as well as a broad range of biological, biochemical or physiological relationships. In many areas that use rigidly structured databases for the management of information, the new technology will greatly benefit users thanks to its high degree of flexibility and the large number of access paths that confer meanings. | ||||||
| SensScreen Technologies GmbH | Biotech | Laboratory Techniques, Proteomics | Development and production of magnetic particles for highly sensitive bioseparation | Stuttgart | Dr. Jochen F. Peter (Managing Director) | 2009 | Silberburgstrasse 144 D-70176 Stuttgart Mobil: +49 (0) 173-7069734 | jochen.peter@sensscreen.com | www.sensscreen.com | SensScreen Technologies GmbH develops and produces magnetic nano- and microparticles as well as new methods for the highly sensitive bioseparation of peptides and proteins from the secretome of cultivated cells or human fluids. SensScreen Technologies has developed an award-winning technology platform that enables the quick and gentle isolation of highly pure proteins from cell culture supernatants for example. Another major focus is the ultrasensitive detection of secreted peptides and proteins for the optimisation of cell culture methods. The technology can be used in research carried out at universities, research institutes and companies as well as in the industrial production of proteins and peptides. | ||||||
| micro-biolytics GmbH | Biotech | Trade/Distribution, Laboratory Techniques | Services for the pharmaceutical industries | Esslingen | Andreas Wolf (CEO) Ralf Masuch (CSO) | 2001 in Freiburg | Schelztorstraße 54 D-73728 Esslingen am Neckar Tel.: +49 711 901-211-230 Fax: +49 711 901-211-900 | www.micro-biolytics.com | The major focus of micro-biolytics GmbH is the provision of services for the pharmaceutical industry. The current spectrum of services offered ranges from the development of individual applications to service measurements in combination with statistical and mathematical data analysis to the integration of the patented AquaSpec technology into the production process of the pharmaceutical industry. micro-biolytics GmbH’s AquaSpec technology, which these days is marketed around the globe, is considerably more efficient than previous methods in the analysis of potential pharmaceutically active substances. The AquaSpec method is based on infrared spectroscopy in the medium infrared range; it is a sensitive and specific spectroscopic method for the analysis of aqueous or organic samples. micro-biolytics GmbH has further developed the method, making it fit for industrial application. Based on its patented AquaSpec technology, the company offers fully automated analysis systems for use in pharmaceutical drug development, process control and medical diagnostics. | |||||||
| Schärfe System GmbH | Biotech | Diagnostics, Trade/Distribution, Laboratory Techniques | Development, production and marketing of cell analysers for cell culture control | Reutlingen | Karin B. Schärfe (CEO) | 1987 | Krämerstrasse 22 72764 Reutlingen Germany Tel.: +49 (0)7121-38786-0 Fax: +49 (0)7121-38786-99 | www.casy-technology.com | CASY®-Technology is the ideal solution for parallel determination of cell debris, vital cells, dead cells and cell aggregates, with applications ranging from cell number determination right through to the characterisation of cytotoxic investigations. The CASY®-Technology product portfolio includes tools such as cell counters, computerised cell analysers with integrated data processing capabilities and the accompanying consumables and accessories. The cell vitality techniques utilised in the field of cell culture control traditionally involve the use of a dye that often has a cytotoxic effect. However, Schärfe System GmbH offers an effective alternative with its Electrical Current Exclusion (ECETM) solution, which is an integral component of CASY®-Technology. | |||||||
| c-a-i-r biosciences GmbH | Biotech | Drug Development | Research and development of new agents for treating inflammatory processes | Tübingen | Dr. Wolfgang Albrecht (CEO) | TechnologiePark Tübingen/Reutlingen Paul-Ehrlich-Str. 15 72076 Tübingen Phone: +49 (0)7071–9652080 | info@cair-biosciences.de | www.cair-biosciences.de | c-a-i-r biosciences GmbH is a start-up company funded by the German Federal Ministry of Education and Research (BMBF) as part of the BioProfile programme. The world-renowned ratiopharm Group from Ulm is lead investor. This new company specialises in the research and development of new low-molecular, anti-inflammatory drugs for the treatment of diseases such as rheumatoid arthritis, chronic inflammatory intestinal diseases, asthma and psoriasis. The research focuses on protein kinases, which perform a key function in the regulation of pro-inflammatory signal molecules (TNF-alpha, interleukin-1beta), and on enzymes of the arachidonic acid cascade (cyclooxygenases, 5-lipoxygenase). The company was founded on the basis of developments and patents originating from long-term research collaboration between the ratiopharm Group and Professor Stefan A. Laufer from the Institute of Pharmacy at Tübingen University. As a result of the protein kinase inhibitor project, a drug candidate has already been pre-clinically developed and tested on humans in an initial study. c-a-i-r biosciences has now set its sights on developing further drug candidates for clinical testing. | |||||||
| German Centre for Biomaterials and Organ Replacement | Institute | Services, Regenerative Biology, Process Engineering | Development of biomaterials and organ replacements | Denkendorf | Prof. Dr. Ing. H. Planck (Chairman) Prof. Dr. med. H.D. Becker (Vice Chairman) Prof. Dr. human. biol. Lutz Claes (Secretary) Prof. Dr. med. Karl-Klaus Dittel (Auditor) Dr.-Ing. Martin Dauner (Coordinator) | Körschtalstr. 26 D-73770 Denkendorf Tel: +49(0)711-93400 Fax:+49(0)711-9340297 | bmoz@itv-denkendorf.de | www.itv-denkendorf.de | The German Centre for Biomaterials and Organ Replacement Stuttgart-Tübingen (BMOZ) brings together the scientific and clinical institutions of the universities of Stuttgart and Tübingen and is being funded by the German Federal Ministry of Education and Research (BMBF) for a period of five years as part of the “Ma-Tech” programme. BMOZ has obtained additional financial support from the Baden-Württemberg Ministry of Science, Research and the Arts, the University of Tübingen and project-related industry funds. BMOZ’s main activity is the coordination of research projects funded by the BMBF and its industrial partners. The goal of the Centre is to give industry a basis for the concerted development of biomaterials and organ replacements. Besides basic research, the partners are therefore mainly focused on application-oriented developments in cooperation with pharmaceutical and medical device companies. The Centre’s activities are: * Design and development planning * Polymer synthesis and processing * Surface modification (plasma, wet, biochemistry) * Implants & instruments: development / production * Purification and sterilisation methods * Pharmacological studies * Tissue engineering * Testing (biomechanical, physical-chemical, biological) * In vivo animal studies * Clinical trials The laboratories of the research institutes that are part of BMOZ (ITV, IGB, NMI) along with the animal experiment institute at the University of Tübingen are all accredited by the Zentralstelle der Länder für die Gesundheit (ZLG) for the medical product area. | |||||||
| IDENTXX GmbH | Biotech | Services, Ecology/Environment | Early detection of infected seeds using DNA probe technology | Stuttgart | Frank Brändle (Managing Director) | IDENTXX GmbH Maybachstrasse 50 70469 Stuttgart Pflanzenschutz FON +49 (0)711 93343651 Herbologie FON +49 (0)711 93343653 Labor FON +49 (0)711 93343654 FAX +49 (0)711 93343659 | info@identxx.de | www.iden | With state-of-the-art biomolecular methods the young company IDENTXX meets the challenge to sustain and improve crop health. Only an exact and reliable identification of pathogens and resistances in seeds and plants can avoid crop damage and yield losses. IDENTXX develops tailor-made solutions in diagnostics for weed science and plant protection. Our services focus on the detection of plant pathogens and herbicide resistances, for which the latest biomolecular methods are applied. The methods are individually and continuously adapted to the problem at hand. The services of IDENTXX benefit clients in the sectors of agricultural production of arable and special crops as well as ornamentals. It may play a key role in improving seed production, plant breeding, development of plant protection products, and is targeting agricultural associations and public authorities. IDENTXX runs its own brand-new laboratory and greenhouses under the direction of experienced specialists. Hence, it enables the application of the latest biomolecular technologies in combination with classical greenhouse testing. | |||||||
| Interfaculty Institute for Biochemistry (IFIB) | Institute | Chemistry | Interdisciplinary biochemical and biomedical research | Tübingen | Prof. Dr. Thilo Stehle (Institute Director) Dr. Klaus Möschel (Managing Director) | Hoppe-Seyler-Str. 4 72076 Tübingen Tel.: +49 (0)7071-2973341 | klaus.moeschel@uni-tuebingen.de | www.ifib.uni-tuebingen.de | The Interfaculty Institute for Biochemistry (IFIB) at the University of Tübingen was established in 2004 by the Faculty of Chemistry and Pharmacy and the Faculty of Medicine with the goal of carrying out interdisciplinary biochemical and biomedical research. In addition, the IFIB is closely linked with the Centre of Plant Molecular Biology (ZMBP) in Tübingen. Modern biochemical and biomedical research focuses on complex issues. Cooperation between different groups of researchers around the world is therefore absolutely necessary. The IFIB participates in many international collaborations and is part of numerous research networks. | |||||||
| International Reference Centre DNA Viruses | Institute | Medicine, Genomics | International reference centre for the genomics and diagnosis of viruses with small circular DNA | Stuttgart | Prof. Dr. Holger Jeske | Universität Stuttgart Biologisches Institut Pfaffenwaldring 57 D-70550 Stuttgart Tel. +49 (0)711-68565070 | holger.jeske@bio.uni-stuttgart.de | www.uni-stuttgart.de | Researchers at the University of Stuttgart, in cooperation with two academic groups led by Prof. Dr. Eduardo Rodríguez Bejarano, Universidad de Malaga, and Dr. Bruno Gronenborn, Institut des Sciences du Végétal, Paris along with the company Qiagen as industrial partner and specialist in diagnostic test methods, have been operating an international virus reference centre since 2007. The centre receives a total of 1.2 million euros in funding from the EU for a period of three years, of which 600,000 euros go towards the research carried out by the Stuttgart researchers. A major focus of the centre is the establishment of a gene bank to store and characterise viral DNA from across the globe. The Stuttgart scientists are specifically focusing on Gemini viruses with a two-component genome, the Spanish scientists are working on Gemini viruses with a one-component genome and the French scientists are researching nanoviruses. All these viruses are known to cause numerous plant diseases. | |||||||
| Life Science Center Hohenheim (LSC) | Institute | Services, Genomics | Life sciences research with a special focus on the food chain – from production to consumer behaviour, as well as biological signals. | Stuttgart | Prof. Dr. Andreas Schaller (Director) Dr. Caroline Liepert (Managing Director) Prof. Dr. Andreas Kuhn (Spokesperson Division 1) Prof. Dr. Herbert Schmidt (Spokesperson Division 2) Prof. Dr. Thilo Streck (Spokesperson Division 3) | Fruwirthstraße 12 D-70599 Stuttgart Tel.: +49 (0)711-45924026 | lsc@uni-hohenheim.de | www.lsc.uni-hohenheim.de | The Life Science Centre (LSC) is a research centre attached to the University of Hohenheim that is directly assigned to the University’s rectorate. It offers life science-oriented disciplines a central platform for research projects and scientific developments. The LSC has a special focus on the food chain and hopes to advance its work through inter- and transdisciplinary approaches. In addition, the Centre also supports bordering basic-research oriented sciences, in particular in the field of biological signals. In analogy to the thematic research priorities of the Centre, the LSC has three scientific divisions: Division 1: Biomolecular signals and genomics Division 2: Quality and biofunctionality of food Division 3: Ecosystems and resource management The LSC has a central service unit that uses state-of-the-art methods and devices for genome and proteome analysis. | |||||||
| Max Planck Institute for Developmental Biology | Institute | Genomics | Basic research in the fields of biochemistry, molecular biology and genetics as well as cell and evolutionary biology | Tübingen | Prof. Dr. Detlef Weigel (Managing Director) Directors: Prof. Dr. Andrei Lupas Dr. Elisa Izaurralde Prof. Dr. Christiane Nüsslein-Volhard Prof. Dr. Ralf Sommer Prof. Dr. Gerd Jürgens Prof. Dr. Detlef Weigel | Spemannstraße 35 D-72076 Tübingen Tel.: +49(0)7071-601350 Fax: +49(0)7071-601300 | mpi.entwicklungsbiologie@tuebingen.mpg.de | www.eb.mpg.de | The Max Planck Institute for Developmental Biology carries out basic research in the fields of biochemistry, molecular biology and genetics as well as cell and evolutionary biology. It has a staff of around 325 and is located on the Max Planck campus in Tübingen. The MPI for Developmental Biology is one of 80 institutes and research institutes belonging to the Max Planck Society for the Promotion of Science. The institute was established in 1937 as a working group of the Unit for Virus Research attached to the Kaiser Wilhelm Institutes of Biochemistry and Biology in Berlin-Dahlem, which was renamed MPI for Developmental Biology when it relocated to Tübingen 40 years later. The working groups run by the institute directors focus on the evolutionary history of proteins and protein systematics (Lupas), the genetics of embryonic development in Drosophila melanogaster and zebrafish (Nüsslein-Volhard), the evolution of developmental processes (Sommer), the integration of environmental and genetic factors during the development of Arabidopsis thaliana (Weigel), the post-transcriptional mechanisms of gene expression (Izaurralde) and the embryonic development of Arabidopsis thaliana (Jürgens). | |||||||
| Ornamental Bioscience | Biotech | Trade/Distribution | Development and marketing of transgenic ornamental plants | Stuttgart | Christian Klemm (Managing Director) | Hanfäcker 10 70378 Stuttgart Germany Phone: +49 (0)711-95325-88 Fax: +49 (0)711-95325-40 | info@ornamental-bioscience.com | www.ornamental-bioscience.com | Ornamental Bioscience is a new joint venture based in Stuttgart in which the German Selecta Group and the US company Mendel Biotechnology Inc. both have a stake. The company develops and markets transgenic ornamental plants. Ornamental Bioscience combines Mendel's technological know-how in the field of drought, cold, frost and pathogen resistance with Selecta's experience in the field of cultivation, production and sale of ornamental plants. Ornamental Bioscience has so far transformed and tested plant species from the Selecta product range such as petunias, poinsettias, New Guinea impatiens (Busy Lizzies) and geraniums. Now, further species are to be added through cooperation arrangements with other cultivators. Family business Selecta Klemm GmbH & Co. KG is one of the world’s leading cultivation and propagation companies for vegetatively reproducible ornamental plants. Selecta has acquired numerous patents and plant variety protection rights for cut flowers and bedding, balcony and pot plants over the past 40 years. The company has seven main sites worldwide with production, cultivation and sales facilities; the headquarters are in Stuttgart. Selecta has been active in biotechnology since 1996. Selecta Klemm was involved in the Australian company Florigene’s development of the blue carnation, which is as yet the only transgenic ornamental plant that has been approved for marketing in Europe | |||||||
| Centre for Regenerative Biology and Regenerative Medicine, ZRM | Institute | Services, Regenerative Biology, Education | Support of regenerative biology and medicine projects | Tübingen | Managing Director: Prof. Dr. Thomas Skutella Deputy Managing Director: Prof. Dr. Wilhelm K. Aicher Coordinator/CEO: Prof. Dr. Konrad Kohler | Paul-Ehrlich-Straße 15 D-72076 Tübingen Tel.: +49 7071 29-85034 Fax: +49 7071 29-4553 | info@regmed.uni-tuebingen.de | www.regmed.uni-tuebingen.de | The Centre for Regenerative Biology and Medicine zrm is a joint facility of the University Hospital Tübingen and the School of Medicine of the Eberhard Karl University of Tübingen. The centre supports projects in the fields of regeneration biology and regenerative medicine from basic research to clinical application. Major foci are stem cell research, cell therapy and the development of molecular regenerative strategies and biomaterials. The zrm develops and coordinates courses and seminars and offers a wide spectrum of services to its partners in the Regenerative Medicine network, ranging from consulting and assistance with projects to access to human cell and tissue banks. While consulting and networking services are provided free of charge by the centre, services involving a greater investment in time and material are usually charged. The members of the zrm come from biology and medicine departments of the University of Tübingen and the University Hospital. Scientists and physicians cover the entire spectrum of expertise from basic research to clinical research all the way to therapeutic application. The zrm comprises the following institutions at the University of Tübingen: * Anatomical Institute, Department of Experimental Embryology and Tissue Engineering * University Hospital of Tübingen, Department of General, Visceral and Transplantation Surgery * University Hospital of Tübingen, Department of Dermatology * University Hospital of Tübingen, Internal Medicine I * University Hospital of Tübingen, Internal Medicine II * University Hospital of Tübingen, Internal Medicine III * University Children’s Hospital Tübingen, Department I (General Paediatrics, Haematology, Oncology) * Clinic for Neurology, Department for Neurodegenerative Disorders * University Hospital of Tübingen, Hospital of Neurosurgery * University Hospital of Tübingen, Orthopaedic Clinic * University Hospital of Tübingen, Hospital of Radiology, Division for Diagnostic Radiology * University Hospital of Tübingen, Department of Radiation Oncology * Institute of Clinical and Experimental Transfusion Medicine * University Hospital of Tübingen, Department of Thoracic, Cardiac and Vascular Surgery * University Hospital of Tübingen, Clinic for Urology * University Hospital of Tübingen, Centre of Dentistry, Oral Medicine and Maxillofacial Surgery * University Hospital of Tübingen, Institute of Medical Microbiology and Hygiene | |||||||
| Center Systems Biology (CSB) | Institute | Information Technology | Research and education in the field of systems biology | Stuttgart | Prof. Dr.-Ing. Dr.h.c. Matthias Reuss | Zentrum Systembiologie (CSB) Universität Stuttgart Allmandring 31 70569 Stuttgart Tel.: +49 (0)711-68569926 Fax: +49 (0)711-68565164 | witteler@zsb.uni-stuttgart.de | www.centersysbio.uni-stuttgart.de | The Center Systems Biology (CSB) is an interfaculty research institution at the University of Stuttgart. The CSB focuses on interfaculty and interdisciplinary research and education in the field of sys-tems biology. Its goal is to move on from the analysis of individual components of a biological system in order to reach a holistic understanding of the system as a whole and progress from a qualitative descriptive to a quantitative, theory-based and predictive biology. A particular feature of the systems biological activities of the University of Stuttgart within the CSB is the close co-operation between the biological, engineering and systems sciences. The interdisciplinary integration of the biological, systems and engineering sciences is the Uni-versity of Stuttgart’s Germany-wide unique selling point. The CSB’s board of directors is composed of members of the faculties involved. It is supported by a scientific advisory board composed of internationally renowned scientists in the field of sys-tems biology. The CSB’s activities are: • Initiation and coordination of research projects. • The joint acquisition and administration of funds for research projects. • The organisation of joint scientific events and providing information to professionals about research at the CSB. • The publication of research and progress reports. • The interfaculty coordination of measures for the appointment and replacement of profes-sors in the field of systems biology. • The establishment of junior research groups. • Involvement in the establishment of an international master’s “Systems Biology” course. Current research activities reflect the structure of the CSB and are divided into three areas: (1) Basic principles of systems biology, (2) applications in medicine and (3) applications in biotech-nology. A number of projects are also carried out in cooperation with the University of Tübingen and the University of Hohenheim, in which the systems biology activities of the partners are brought to-gether. The CSB commenced activities in 2007 with the financial support of the Baden-Württemberg Ministry of Science, Research and the Arts and the University of Stuttgart. The CSB has since initiated cooperative research projects that receive funding through the German Ministry of Edu-cation and Research (BMBF). | |||||||
| JatroSolutions GmbH | Biotech | Services, Ecology/Environment | Development of concepts for the integrated production of biofuels and animal feed on waste land | Stuttgart | Prof. Dr. Klaus Becker (Managing Director) Dr. George Francis (Director of Research and Business Development) | Wollgrasweg 49 70599 Stuttgart-Hohenheim Tel.: +49 (0)711-451071420 Fax: +49 (0)711-451071421 | www.jatrosolutions.com | The company’s key focus area is Jatropha curcas, an oil seed plant that is indigenous to almost all tropical countries and that grows on poor soils in extreme climatic conditions. Due to its versatility, the plant is well suited to the production of biofuels, the recultivation of waste land, CO2 sequestration as well as to the creation of local jobs and income. JaotroaSolutions develops concepts for sustainable development in the tropics and subtropics as well as offering comprehensive process-oriented consulting and supporting the development of international trade relationships. | ||||||||
| Nascatec GmbH | Biotech | Laboratory Techniques | Development and production of high-tech solutions in microsystems technology and nanoanalysis | Stuttgart | Wolfgang Barth (CEO) | Wankelstraße 14 70563 Stuttgart Tel.: +49 (0)711-686894-90 Fax: +49 (0)711-686894-99 | info@nascatec.com | Nascatec GmbH, a world market leader in high-resolution optical near-field microscopy, develops and produces high-tech solutions in the microsystems technology and nanoanalysis sectors. Nascatec products are deployed in all fields of nano- and microtechnology. The company has developed not only the first piezoresistive AFM sensors but also the world’s first SNOM sensor based on cantilever technology, which analyses surfaces using optical measurement. For example, Nascatec has equipped both the ESA’s Rosetta mission and NASA’s Stardust mission with Nascatec sensors. The company’s core business focuses on the development, prototype production and manufacture of SPM/AFM sensors, SNOM sensors and micro-nanomanipulators for applications in research and development, surface characterisation, process controls and biotechnology. Now, the product portfolio is to be expanded, with the aim of exploiting the potential of nanomodules for the life science sector. | ||||||||
| ibt - immunological & biochemical testsystems GmbH | Biotech | Diagnostics | Development and production of innovative immunoassays | Reutlingen | Aspenhaustrasse 25 72770 Reutlingen Germany Tel: +49 (0)7121-514634 Fax: +49 (0)7121-514635 | info@ibtsystems.de | www.ibtsystems.de | The company, founded as A.F. Schützdeller, Biochemicals (AFSBIO), developed, produced and sold poly- and monoclonal antibodies, proteins and antigens for research into infectious diseases, transcription research, cytokines and growth factors. Shifting its area of focus onto the development and production of innovative immunoassays based on non-radioactively-marked IGFs, the firm renamed itself ibt – immunological & biochemical testsystems GmbH. The firm’s scientific focus currently lies on the field of insulin-like growth factors (IGFs) and insulin-like growth factor binding proteins (IGFBPs). A special biotinylation technology, which ensures the binding of ligands to IGFBPs, IGF receptors and antibodies, is used in the manufacture of biotinylated IGFs and analogue substances. Areas of application for biotinylated IGFs and analogue substances include binding assays, immunoassays, Western ligand blots, immunohistochemistry, immunoprecipitation, flow cytometry and cross-linking experiments. | ||||||||
| Crinotec GmbH | Biotech | Laboratory Techniques, Process Engineering | Development of measurement processes in the field of biosensors and chemosensors | Tübingen | Andreas Fiedler (CEO) | Auf der Morgenstelle 28 72076 Tübingen Germany Tel.: +49 (0)7123-888422 Fax: +49 (0)7123-888455 | info@crinotec.de | www.crinotec.de | ||||||||
| Institute of Textile Technology and Process Engineering Denkendorf ITV | Institute | Research and development in all areas of textile technology and textile machinery construction, biomedical technology, management research | Denkendorf | Prof. Heinrich Planck; Director of the Institute and Head of the Biomedical Technology Division | Körschtalstrasse 26 73770 Denkendorf Germany Postal address: Postfach 11 55 73766 Denkendorf Germany Tel.: +49 (0)711-9340–0 Fax: +49 (0)711-9340-297 | info@itv-denkendorf.de | www.itv-denkendorf.de | The ITV Denkendorf has its roots in Reutlingen where, in 1855, following an initiative from the industry sector, the City of Reutlingen and the Kingdom of Württemberg, a weaving school was founded from which a professional college for spinning, weaving and knitting was formed in 1891. In 1910, the college was extended to include a testing office, with a research institute being added in 1921. As part of its joint industrial research, the ITV Denkendorf supports small to medium-sized companies in their quest to tackle research and development problems. The firm’s divisions, which essentially encompass the entire domain of textile technology and associated specialities, also focus on this key mission. The ITV is part of the German Institutes of Textile and Fibre Research (DITF) in Denkendorf, a research centre that focuses comprehensively on the requirements of the textile industry. The ITV Denkendorf’s research and development work, along with its measuring, testing and certification activities, are carried out in the following areas and focus fields: Staple fibre technology/filament yarn finishing/knitting technology/fleece technology/weaving technology sustainable raw materials/plant fibres Technical textiles/surface technology/environmental technology, biomedical technology, including tissue engineering, medical products, implants, plus material and implant testing Process control/automation/measuring technology | Hendrik Hauss (Hendrik.Hauss@itv-denkendorf.de) | Associated project: liver reactor; subproject A | ||||||
| Centre for Plant Molecular Biology | Institute | Plant molecular biology | Tübingen | Managing Director (alternating) | c/o Silvia Röcker Auf der Morgenstelle 1 72076 Tübingen Tel.: +49 (0)7071-2978805 Fax: +49 (0)7071-293287 | silvia.roecker@zmbp.uni-tuebingen.de | www.zmbp.uni-tuebingen.de | Ever since its foundation in May 1999 as an interfaculty and interdisciplinary research priority within the Faculties of Biology, Chemistry and Pharmacy at the University of Tübingen, the Centre for Plant Molecular Biology has occupied a leading international position in the research and education of young scientists. This is evident from the large number of publications in leading scientific journals, comprehensive third-party funding, strong involvement in national and international research associations and the excellent evaluation by an independent scientific advisory board. In addition, over the last eight years, more than 20 ZMBP scientists have been appointed professors at German and international institutions. This is also clear evidence of the stimulating research environment at the ZMBP. Flat hierarchies, global budget, independent research and technological support from the ZMBP’s central service institutions provide junior researchers and group leaders optimal conditions to work and research in 16 independent groups of researchers. This modern structure, continuous technological development and quality control by the scientific advisory board ensure the international competitiveness and scientific excellence of the ZMBP. The latest recognition of the Centre’s capabilities was the German Council of Science and Humanities’ (Wissenschaftsrat) decision to grant the ZMBP a new research building. Further information can be found at http://www.zmbp.uni-tuebingen.de. Together with the Max Planck Institute for Developmental Biology and the University of Hohenheim, the ZMBP has initiated the “RegioPlantScience” research consortium with the goal of more effectively coordinating research and education in the field of plant sciences in the region. | ||||||||
| Friedrich-Miescher Laboratory | Institute | Biological research | Tübingen | Prof. Dr. Christiane Nüsslein-Volhard | Spemannstraße 39 D-72076 Tübingen, Germany Tel.: +49 (0)7071-601800 Fax: +49 (0)7071-601801 | www.fml.mpg.de | The Friedrich-Miescher Laboratory (FML) is a research institute belonging to the Max Planck Society, named after Friedrich Miescher, a renowned Swiss biologist who discovered DNA whilst carrying out research in Tübingen. The Institute was established in 1969 with the objective of giving outstanding young scientists the opportunity to carry out research within independent research groups. The projects all last five years. The FMO is on the Max Planck Campus in Tübingen, which also hosts the Max Planck Institutes for Developmental Biology and Biological Cybernetics. The FML consists of up to four independent research groups headed by junior group leaders who work on different aspects of biology. The Antonin lab deals with nuclear envelope dynamics, the Hauf lab with chromosomal segregation, the Ivanov lab with the cohesion of sister chromatids and the Rätsch lab with machine learning in biology. | |||||||||
| Max Planck Institute for Biological Cybernetics | Institute | Clarification of cognitive processes | Tübingen | Prof. Dr. Bernhard Schölkopf (Managing Director) | Spemannstraße 38 D-72076 Tübingen Mailing Adress: Postfach 21 69 D-72012 Tübingen Tel.: +49(0)7071-601510 Fax: +49(0)7071-601520 | www.kyb.mpg.de | The Max Planck Institute for Biological Cybernetics in Tübingen works on the clarification of cognitive processes on the experimental, theoretical and methodological level. The "Cognitive Human Psychophysics" (Director: Prof. Dr. Heinrich Bülthoff; formed in 1993) and "Physiology of Cognitive Processes" departments (Director: Prof. Dr. Nikos Logothetis; founded in 1997) employ complementary methodological approaches for the systems analysis of complex processes in the brain of primates. The "Empirical Inference for Machine Learning and Perception" department (Director: Prof. Dr. Bernhard Schölkopf; founded in 2001) works in the field of statistical learning theory and its application in various fields - ranging from computer vision to bioinformatics. The "High-Field Magnetic Resonance Centre" (Acting Director: Prof. Dr. Bernhard Schölkopf; founded in 2003) works on the development of new contrast agents as well as the methodical enhancement and application of imaging techniques (major focus: magnetic resonance). | |||||||||
| Max Planck Institute for Metals Research | Institute | Basic materials research | Stuttgart | Prof. Dr. Joachim Spatz (Acting Director) | Heisenbergstr. 3 70569 Stuttgart Tel.: +49 (0)711-6890 Fax +49 (0)711-6891010 | www.mf.mpg.de | The Max Planck Institute for Metals Research was founded in 1921 as one of the first Kaiser Wilhelm Institutes and has been a leading research institution in this field ever since. Since its relocation to Stuttgart in the 1930s, the Institute has been closely connected with the University of Stuttgart. Nowadays, the Institute’s main research areas are the basic functions and applications of nano-biosystems. Its close connections with the traditional disciplines of physics, chemistry and the life sciences enable the Institute to work with exciting, basic issues in an interdisciplinary way and at the border of the aforementioned disciplines. Up to 400 scientists, including around 150 foreign scientists, focus on research, with the support of technicians and other staff members. The scientists are spread around eight departments, each one managed by a director and scientific member of the Max Planck Society (Prof. Dr. Siegfried Dietrich, Prof. Dr. Manfred Rühle, Prof. Dr. Ir. Eric Mittemeijer, Prof. Dr. Gisela Schütz, Prof. Dr. Joachim Spatz –three departments do not currently have a director in place). Five junior research groups have recently been established at the MPI-MF. The junior research groups run for a period of five years and are led by excellent junior researchers (Dr. Dagmar Goll, Dr. Frauke Gräter, Dr. Raquel Martin, Dr. Ralf Richter, Dr. Sylvie Roke). In addition, Prof. Dr. Clemens Becher, Head of the Institute of Physics II at the University of Stuttgart, was appointed Max Planck Fellow in 2007. The Institute has a world-class reputation in the analysis of materials, including methods of X-ray diffraction and absorption, neutron scattering, electron and X-ray microscopy, surface analytics as well as calorimetric, magnetic and mechanic measurement techniques. This broad range of methods enables the Stuttgart researchers to gain detailed insights into complex material phenomena. “From model systems to implementation of model systems up to materials with real microstructures and application potential” – this is the development chain at the MPI-MF. Although the chain is mainly basic research-based, this type of research nevertheless often enables the Institute to cross over to application-oriented research. The Institute makes major contributions to the development of materials for practical applications for use in energy, transport, information technology and the life sciences. This basis for technical innovations is based on active and successful collaborations with industrial companies. |
